Rare diseases

Tocilizumab gets PBS nod for GCA

The Pharmaceutical Benefits Advisory Committee has recommended PBS listing for tocilizumab (Actemra) for the treatment of giant cell arteritis (GCA). At its March meeting the PBAC acknowledged that trial data showed that tocilizumab injection (weekly or fortnightly) was associated with a statistically significant increase in response rates compared with placebo plus a 52-week prednisone taper, ...

Already a member?

Login to keep reading.

© 2021 the limbic